Sonoma Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Sonoma Pharmaceuticals es Amy Trombly , nombrado en Sep 2019, tiene una permanencia de 5.17 años. compensación anual total es $726.54K, compuesta por 44.7% salario y 55.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.57% de las acciones de la empresa, por valor de €19.46K. La antigüedad media del equipo directivo y de la junta directiva es de 3.1 años y 6.2 años, respectivamente.

Información clave

Amy Trombly

Chief Executive Officer (CEO)

US$726.5k

Compensación total

Porcentaje del salario del CEO	44.7%
Permanencia del CEO	5.2yrs
Participación del CEO	0.6%
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	6.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Amy Trombly en comparación con los beneficios de Sonoma Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$4m
Jun 30 2024	n/a	n/a	-US$5m
Mar 31 2024	US$727k	US$325k	-US$5m
Dec 31 2023	n/a	n/a	-US$5m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$6m
Mar 31 2023	US$560k	US$319k	-US$5m
Dec 31 2022	n/a	n/a	-US$7m
Sep 30 2022	n/a	n/a	-US$6m
Jun 30 2022	n/a	n/a	-US$5m
Mar 31 2022	US$643k	US$318k	-US$5m
Dec 31 2021	n/a	n/a	-US$6m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	US$580k	US$300k	-US$5m
Dec 31 2020	n/a	n/a	-US$3m
Sep 30 2020	n/a	n/a	-US$4m
Jun 30 2020	n/a	n/a	-US$5m
Mar 31 2020	US$386k	US$153k	-US$4m

Compensación vs. Mercado: La compensación total de Amy($USD726.54K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD472.15K).

Compensación vs. Ingresos: La compensación de Amy ha aumentado mientras la empresa no es rentable.

CEO

Amy Trombly (56 yo)

5.2yrs

Permanencia

US$726,543

Compensación

Ms. Amy M. Trombly, Esq. has been Chief Executive Officer of Sonoma Pharmaceuticals, Inc. since September 27, 2019 and serves as its President and also serves as its Director since July 22, 2022. She is a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Amy Trombly	CEO, President & Director	5.2yrs	US$726.54k	0.57% € 19.5k
Jerome Dvonch	Chief Financial Officer	1.6yrs	US$307.46k	0.32% € 10.7k
Bruce Thornton	Executive VP	4.6yrs	US$658.67k	0.58% € 19.6k
John Poggetto	Controller	1.3yrs	US$479.59k	0.056% € 1.9k

3.1yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de O8Z se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Amy Trombly	CEO, President & Director	2.3yrs	US$726.54k	0.57% € 19.5k
John McLaughlin	Lead Independent Director	11.7yrs	US$65.00k	0.020% € 686.6
Philippe Weigerstorfer	Independent Director	6.2yrs	US$47.50k	0% € 0
Jay Birnbaum	Independent Director	17.6yrs	US$55.00k	0.021% € 727.3
Hye Chung	Scientific Advisory Board	1.3yrs	sin datos	sin datos

6.2yrs

Permanencia media

70.5yo

Promedio de edad

Junta con experiencia: La junta directiva de O8Z se considera experimentada (6.2 años de antigüedad promedio).

Sonoma Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 14, 2024

Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller

Sonoma Pharmaceuticals, Inc. Announces CFO Changes

Sonoma Pharmaceuticals, Inc. Announces Resignation of Jerry Dvonch as Chief Financial Officer

Recent updates

Sonoma Pharmaceuticals, Inc. Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel

Sonoma Pharmaceuticals, Inc. to Exhibit At MEDICA 2024 in Dusseldorf

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Sonoma Pharmaceuticals, Inc. and Its Partner, the MicroSafe Group DMCC, Announce That the Australian Therapeutic Goods Administration Approves Extended Claims for Nanocyn Disinfectant and Sanitizer

First quarter 2025 earnings released: US$0.067 loss per share (vs US$0.29 loss in 1Q 2024)

New major risk - Revenue and earnings growth

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Aug 14, 2024

Full year 2024 earnings released: US$0.53 loss per share (vs US$1.52 loss in FY 2023)

No longer forecast to breakeven

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores

Nasdaq Grants Extension to Sonoma Pharmaceuticals to Regain Minimum Bid Price Requirement

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.785679 million.

Third quarter 2024 earnings released: US$0.079 loss per share (vs US$0.62 loss in 3Q 2023)

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-The-Counter Skincare Product for Daily Use

No longer forecast to breakeven

Sonoma Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $0.392077 million.

No longer forecast to breakeven

Sonoma Pharmaceuticals, Inc. Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation At the Symposium on Advanced Wound Care Fall Conference

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

Sonoma Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

Sonoma Pharmaceuticals Receives Letter from The Nasdaq Stock Market LLC Regarding Non-Compliance with Minimum Bid Price for its Common Stock

No longer forecast to breakeven

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals, Inc. for Reliefacyn Advanced

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.29 loss in 1Q 2023)

Sonoma Pharmaceuticals, Inc. Announces Appointment of Hye Jin Chung to Scientific Advisory Board

Sonoma Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Sonoma Pharmaceuticals, Inc. Appoints John Dal Poggetto as Controller

Full year 2023 earnings released: US$1.52 loss per share (vs US$1.92 loss in FY 2022)

Sonoma Pharmaceuticals, Inc. Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

Third quarter 2023 earnings released: US$0.62 loss per share (vs US$0.31 loss in 3Q 2022)

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

Second quarter 2023 earnings released: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)

Sonoma Pharmaceuticals, Inc. Launches Two New Dermatological Products

Sonoma Pharmaceuticals, Inc. Announces CFO Changes

Sonoma Pharmaceuticals, Inc. Announces Resignation of Jerry Dvonch as Chief Financial Officer

Sonoma Pharmaceuticals, Inc. Announces Close of Office in Woodstock, Georgia Effective on or Before December 31, 2022

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Insufficient new directors

Sonoma Pharmaceuticals, Inc. and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S

Insufficient new directors

Sonoma Pharmaceuticals, Inc. Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa

Insufficient new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.075 profit in 2Q 2021)

Insufficient new directors

Insufficient new directors

Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe

Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.81 loss in 3Q 2020)

Sonoma Pharmaceuticals, Inc. and Microderm Technologies Ltd. Announce That Dermodacyn Disinfecting Solution Is Now Available in Hong Kong and Thailand

Sonoma Pharmaceuticals, Inc. Announces Partnership with Gabriel Science, LLC for Dental Markets

Sonoma Pharmaceuticals, Inc. and Crown Laboratories, Inc. Announce Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products

Sonoma Pharmaceuticals, Inc. announced delayed 10-Q filing

Sonoma Pharmaceuticals and MicroSafe Group Announces that Health Canada Authorized Nanocyn® Disinfectant & Sanitizer to be Sold in Canada as a Hard-Surface Disinfectant under COVID-19 Interim Measure

Sonoma Pharmaceuticals, Inc. Plans to Relocate Remaining Manufacturing to Mexico

Sonoma Pharmaceuticals, Inc. announced delayed annual 10-K filing

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta